Article Text

Download PDFPDF
Long-Term Outcome of Patients With Aortic Aneurysms Taking Low-Dose Aspirin
  1. Chung-Yu Chen, MSc*,
  2. Jiann-Woei Huang, MD,
  3. Charles Tzu-Chi Lee, PhD,
  4. Wen-Ter Lai, MD§,
  5. Yaw-Bin Huang, PhD*∥¶
  1. From the *School of Pharmacy, Kaohsiung Medical University, †Division of Cardiovascular Surgery, Department of Surgery, Kaohsiung Medical University Hospital, ‡Department of Public Health, Kaohsiung Medical University, §Department of Internal Medicine, Kaohsiung Medical University Hospital, ∥Graduate Institute of Clinical Pharmacy, Kaohsiung Medical University, and ¶Department of Pharmacy, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
  1. Received September 26, 2012, and in revised form March 24, 2013.
  2. Accepted for publication April 17, 2013.
  3. Reprints: Yaw-Bin Huang, PhD, No. 100, Shihcyuan 1st Rd, Sanmin District, Kaohsiung City 80708, Taiwan, Republic of China. E-mail: yabihu{at}
  4. Financial support was provided by National Science Council (NSC100-2320-B-037-017) and Kaohsiung Medical University Hospital (grant 8R-32).
  5. The authors have no potential conflicts of interest to report.
  6. This study is based in part on data from the National Health insurance Research Database provided by the Bureau of National Health Insurance, Department of Health, Taiwan, and managed by the National Health Research Institutes. The interpretations and conclusions contained herein do not represent those of the Bureau of National Health Insurance, Department of Health, or the National Health Research Institutes.

A Population-Based Cohort Study


Background Limited studies evaluated the association between low-dose aspirin use and abdominal aortic aneurysm (AAA), thoracoabdominal aortic aneurysm (TAAA), and thoracic aortic aneurysm (TAA) treatment. We conducted this study to investigative the association of low-dose aspirin in terms of preventing death and exacerbation of different aortic aneurysms.

Methods This retrospective study identified aortic aneurysm cases between 1999 and 2006 from the National Health Insurance Research Database and used time-dependent methods to determine whether the use of low-dose aspirin reduced the risk of outcomes. Primary outcomes, including a composite outcome of death, aortic dissection, a rupture event, an unruptured event, or surgical repair, and secondary outcomes, the composite end point of death and readmission for aortic aneurysm events, were estimated separately.

Results Two hundred eighty-seven cases were identified. The hazard ratio for the primary outcome in patients taking low-dose aspirin in AAA/TAAA patients at each 90-day interval based on the time-dependent analysis was 1.000 (95% confidence interval [CI], 0.994–1.005), and in TAA patients 1.010 (95% CI, 0.994–1.026) compared with those with no exposure. In terms of the secondary outcomes, the hazard ratio for all-cause mortality was 0.995 (95% CI, 0.988–1.003) for AAA/TAAA patients and 1.008 (95% CI, 0.991–1.026) for TAA patients.

Conclusions From a national population database, we did not find an association between low-dose aspirin exposure and mortality or exacerbation in different aortic aneurysms by using time-dependent analysis. However, adjustments for aneurysms size and smoking status could not be made, which may limit the validity of the study.

Key Words
  • aortic aneurysm
  • aspirin
  • clinical effectiveness

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.